C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say
ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert
You may also be interested in...
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.